Calithera Biosciences, Inc
CALA
CALA was delisted on the 1st of February, 2023.
54 hedge funds and large institutions have $17.9M invested in Calithera Biosciences, Inc in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 12 increasing their positions, 12 reducing their positions, and 14 closing their positions.
4,533% more call options, than puts
Call options by funds: $139K | Put options by funds: $3K
0% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 12
7% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 14
2% less funds holding
Funds holding: 55 → 54 (-1)
34% less capital invested
Capital invested by funds: $27M → $17.9M (-$9.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$941K |
| 2 |
AAA
Affinity Asset Advisors
New York
|
+$511K |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$511K |
| 4 |
EAM
Empery Asset Management
New York
|
+$396K |
| 5 |
Renaissance Technologies
New York
|
+$253K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$653K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$480K |
| 3 |
AFM
Anson Funds Management
Dallas,
Texas
|
-$427K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$370K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$317K |
CALA Hedge Fund Activity: Q1 2022 in Review
54 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Calithera Biosciences, Inc (CALA) for Q1 2022, worth a combined $17.9M — down 34% from $27M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of CALA and 13 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 12 added.
The largest buyer was BVF Inc, adding an estimated $941K. The largest seller was D.E. Shaw & Co, cutting an estimated $653K.
- 54 institutional investors held Calithera Biosciences, Inc (CALA) as of Q1 2022, down from 55 in Q4 2021.
- Funds reported $17.9M of Calithera Biosciences, Inc stock for Q1 2022, down 34% quarter-over-quarter.
- 13 funds opened new Calithera Biosciences, Inc positions in Q1 2022 and 14 closed out, a net change of -1 holder.
- The largest Calithera Biosciences, Inc buyer in Q1 2022 was BVF Inc, an estimated $941K added.
- The largest Calithera Biosciences, Inc seller in Q1 2022 was D.E. Shaw & Co, an estimated $653K sold.
Based on aggregated 13F filings for Q1 2022.